Literature DB >> 3893030

Frequency of Aspergillus fumigatus isolates and antibodies to aspergillus antigens in cystic fibrosis.

H Schønheyder, T Jensen, N Høiby, P Andersen, C Koch.   

Abstract

The frequency of Aspergillus fumigatus isolates from sputum was assessed prospectively during a 22-month period in 156 patients with cystic fibrosis (CF) from one center, and findings were compared to a cross-sectional evaluation of specific IgG and IgA antibodies, occurrence of chronic Pseudomonas aeruginosa infection, and pulmonary function. The prevalence rate for the 22-month period was 40%. Positive A. fumigatus cultures appeared to be independent of the presence or duration of chronic bronchopulmonary Ps. aeruginosa infection, but isolation of A. fumigatus in patients with pseudomonas infection for more than 5 years was associated with notably decreased pulmonary function. Levels of IgG antibodies to a 470,000 daltons A. fumigatus antigen fraction were higher in patients with positive cultures in the observation period than in those without. IgG antibodies to a 25,000-50,000 daltons antigen fraction were directly correlated to A. fumigatus frequency in patients with positive cultures both prior to and during the survey. On the other hand, levels of IgA antibodies to the 470,000 daltons fraction were inversely related to A. fumigatus frequency, suggesting a role of IgA antibodies in the bronchial clearance of aspergilli. Decreased pulmonary function was found to be associated with elevated levels of A. fumigatus antibodies. It is concluded that immune reactions elicited by A. fumigatus may play a role in clearance of the fungus from the airways but also may contribute to lung morbidity in some patients.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893030     DOI: 10.1111/j.1699-0463.1985.tb02860.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Immunol Scand B        ISSN: 0108-0180


  14 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

2.  Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis.

Authors:  A Bauernfeind; R M Bertele; K Harms; G Hörl; R Jungwirth; C Petermüller; B Przyklenk; C Weisslein-Pfister
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

3.  Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.

Authors:  C Koch; N Høiby
Journal:  Thorax       Date:  1991-05       Impact factor: 9.139

4.  Serologic response to Candida albicans and Aspergillus fumigatus in cystic fibrosis.

Authors:  B Przyklenk; A Bauernfeind; G Hörl; G Emminger
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

5.  Specific IgG subclass antibody pattern to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA).

Authors:  M Skov; T Pressler; H E Jensen; N Høiby; C Koch
Journal:  Thorax       Date:  1999-01       Impact factor: 9.139

6.  Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance.

Authors:  Klaus Leth Mortensen; Rasmus Hare Jensen; Helle Krogh Johansen; Marianne Skov; Tacjana Pressler; Susan Julie Howard; Howard Leatherbarrow; Emilia Mellado; Maiken Cavling Arendrup
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

7.  Serum antibodies to Aspergillus fumigatus catalase in patients with cystic fibrosis.

Authors:  H Schønheyder; T Jensen; I H Laessøe; N Høiby; C Koch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

8.  Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center.

Authors:  David A Stevens; Richard B Moss; Cathy Hernandez; Karl V Clemons; Marife Martinez
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of Aspergillus fumigatus Biofilm.

Authors:  Gabriele Sass; Hasan Nazik; John Penner; Hemi Shah; Shajia Rahman Ansari; Karl V Clemons; Marie-Christine Groleau; Anna-Maria Dietl; Paolo Visca; Hubertus Haas; Eric Déziel; David A Stevens
Journal:  J Bacteriol       Date:  2017-12-05       Impact factor: 3.490

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.